USING COMPUTER SIMULATIONS FOR EVALUATING THE EFFICACY OF BREAST CANCER CHEMOTHERAPY PROTOCOLS

The fundamental strategy of chemotherapy is to maximize tumor eradication within the limits of tolerable toxicity to the organism. To demonstrate the use of mathematical models in designing treatment protocols, we modeled the effect of chemotherapy on tumor mass and simulated the outcome of several neoadjuvant protocols for breast cancer disease. The model assumes unperturbed tumor growth, superimposed by periods of tumor regression during treatment applications. It takes into account both cell cycle specific (CCS) and cell-cycle non specific drugs (CCNS). Three possible modes of growth (exponential, Gompertz and power laws) were simulated in the study. The model parameters (such as cytotoxic activity of a given protocol) were estimated by best fit procedure from the clinical data of tumor regression following neoadjuvant treatments. The estimated parameters were then used to simulate various regimens that are employed today in the treatment of adjuvant and metastatic breast cancer. Our results suggest that although high dose chemotherapy (HDT) cannot eradicate overt metastatic disease, it may lead to cure if applied early in the natural history of breast cancer. Moreover, the simulations predict a better response for a rather toxic dose dense regimen, as compared to a more conventional protocol. However, our simulations suggest that a well tolerable continuous protocol is no less efficient. The results of the study provide insights into the effectivity of chemotherapy and may assist in designing better protocols.

[1]  B. Asselain,et al.  Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. , 1994, European journal of cancer.

[2]  Z. Agur,et al.  A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. , 1992, Mathematical biosciences.

[3]  G. Steel Cell loss as a factor in the growth rate of human tumours. , 1967, European journal of cancer.

[4]  Z. Agur,et al.  The Effect of Drug Schedule on Responsiveness to Chemotherapy a , 1987 .

[5]  C. Sarraf,et al.  The nature of cytotoxic drug-induced cell death in murine intestinal crypts. , 1992, British Journal of Cancer.

[6]  S. Rudnick,et al.  Methotrexate cytotoxicity for L5178Y/Asn- lymphoblasts: relationship of dose and duration of exposure to tumor cell viability. , 1982, Cancer research.

[7]  A. K. Laird Dynamics of Tumour Growth: Comparison of Growth Rates and Extrapolation of Growth Curve to One Cell , 1965, British Journal of Cancer.

[8]  W. Gregory,et al.  Mathematical modelling of tumour response in primary breast cancer. , 1996, British Journal of Cancer.

[9]  H. Magdelenat,et al.  Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. , 1989, Journal of the National Cancer Institute.

[10]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. Schabel,et al.  The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors. , 1969, Cancer research.

[12]  J. Murray,et al.  A mathematical model of glioma growth: the effect of chemotherapy on spatio‐temporal growth , 1995, Cell proliferation.

[13]  C. Hudis,et al.  Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. , 1996, Seminars in oncology.

[14]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[15]  S. Rodenhuis,et al.  High-dose chemotherapy regimens for solid tumors. , 1995, Cancer treatment reviews.

[16]  Y. Bignon,et al.  Neoadjuvant chemotherapy in 126 operable breast cancers. , 1992, European journal of cancer.

[17]  R. Simon,et al.  Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. , 1993, Journal of the National Cancer Institute.

[18]  B Drewinko,et al.  Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. , 1981, Cancer research.

[19]  P. Venugopal,et al.  Regrowth resistance in cancer: why has it been largely ignored? , 1995, Cell proliferation.

[20]  Z. Agur,et al.  Effect of the dosing interval on myelotoxicity and survival in mice treated by cytarabine. , 1992, European journal of cancer.

[21]  I. Tannock Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. , 1970, Cancer research.

[22]  N. Davidson Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. , 1996, Seminars in oncology.

[23]  C. Lipschultz,et al.  Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. , 1993, British Journal of Cancer.

[24]  S. Koscielny,et al.  Growth rate, kinetics of tumor cell proliferation and long‐term outcome in human breast cancer , 1989, International journal of cancer.

[25]  Y. Sugiyama,et al.  Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. , 1989, Cancer research.

[26]  L. Norton Evolving concepts in the systemic drug therapy of breast cancer. , 1997, Seminars in oncology.

[27]  S. Emdin,et al.  Mammographic growth rate, DNA ploidy, and S‐phase fraction analysis in breast carcinoma. A prognostic evaluation in a screened population , 1992, Cancer.

[28]  J. Spratt,et al.  Rates of Growth of Pulmonary Metastases and Host Survival , 1964, Annals of surgery.

[29]  M L Mendelsohn,et al.  Analysis of tumor growth curves. , 1968, Journal of the National Cancer Institute.

[30]  F. Stewart,et al.  Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Levine,et al.  Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Deen,et al.  Quantitative dose-response relations for the cytotoxic activity of chloroethylnitrosoureas in cell culture. , 1982, Cancer research.

[33]  D. Marquardt An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .

[34]  I. Tannock Experimental chemotherapy and concepts related to the cell cycle. , 1986, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[35]  M. D’Incalci,et al.  Doxorubicin distribution in human breast cancer. , 1987, Cancer treatment reports.

[36]  P. Langenberg,et al.  Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  V. Devita The influence of information on drug resistance on protocol design. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  J. Schulte‐Mönting,et al.  Ki‐67 immunostaining in human breast tumors and its relationship to prognosis , 1991, Cancer.

[39]  R Simon,et al.  Selecting drug combinations based on total equivalent dose (dose intensity) , 1990, Journal of the National Cancer Institute.

[40]  I. Tannock,et al.  THE RELATION BETWEEN CELL PROLIFERATION AND THE VASCULAR SYSTEM IN A TRANSPLANTED MOUSE MAMMARY TUMOUR , 2007 .

[41]  David J. Yang,et al.  Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  W. Hryniuk,et al.  Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. , 1987, Seminars in oncology.

[43]  B. Gusterson,et al.  High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  L. Norton,et al.  Predicting the course of Gompertzian growth , 1976, Nature.

[45]  Z. Agur,et al.  The growth law of primary breast cancer as inferred from mammography screening trials data. , 1998, British Journal of Cancer.

[46]  J. Lokich,et al.  Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons. , 1992, Cancer.

[47]  L. Norton A Gompertzian model of human breast cancer growth. , 1988, Cancer research.

[48]  Zvia Agur,et al.  Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs , 1988 .

[49]  A. Robidoux,et al.  Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  E. Zucca,et al.  Direct sequence analysis of 14q+ and 18q- chromosome junctions at the MBR and MCR revealing clustering within the MBR in follicular lymphoma. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  G. Hortobagyi,et al.  Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  L. Norton,et al.  Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.

[53]  B. Teicher,et al.  A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[55]  M. I. Saunders,et al.  Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. , 1988, British Journal of Cancer.

[56]  C. Thron A possible bias in growth-kinetic estimates of the thickness of the growing layer in multicellular tumor spheroids. , 1984, Cancer research.

[57]  S. Koscielny,et al.  Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. , 1984, British Journal of Cancer.

[58]  D. Anderson Familial versus sporadic breast cancer , 1992, Cancer.

[59]  R. Gilles,et al.  Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. , 1994, Radiology.

[60]  F. Preffer,et al.  Cell proliferation kinetics in human tumor xenografts measured with iododeoxyuridine labeling and flow cytometry: a study of heterogeneity and a comparison between different methods of calculation and other proliferation measurements. , 1995, Cancer research.

[61]  E. Frei Clinical trials of antitumor agents: experimental design and timeline considerations. , 1997, The cancer journal from Scientific American.

[62]  J. Ross,et al.  Epidemiology of acute leukemia in children and adults. , 1997, Seminars in oncology.

[63]  D. Fournier,et al.  Growth rate of 147 mammary carcinomas , 1980, Cancer.

[64]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.

[65]  P Ubezio,et al.  Increasing 1-beta-D-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics. , 1994, Cancer research.